Best of cannabinoid science this week...
A food study using molecular networking analysis finds that CBD causes anti-obesity effects via alterations of lipids, carbohydrates, amino acids & nucleic acid levels Foodomics Reveals Anti-Obesity Properties of Cannabinoids from Hemp Oil https://pubmed.ncbi.nlm.nih.gov/36382382
In long COVID patients, a combination of PEA & luteolin (a flavonoid commonly paired with PEA) helped with neural plasticity in the motor cortex as well as the activity of GABA (the brain’s primary inhibitory neurotransmitter) Co-ultramicronized palmitoylethanolamide/luteolin normalizes GABAB-ergic activity and cortical plasticity in long COVID-19 syndrome https://pubmed.ncbi.nlm.nih.gov/36455453
A case report of using CBD-rich cannabis for a patient with hypophosphatasia (a rare genetic disorder of impaired mineralization of bones & teeth that includes muscle pain & neurological symptoms) found that it led to a significant pain reduction, a discontinuation of opioids & resumption of her work as a physician
Medical Cannabinoids as Treatment for Hypophosphatasia-Related Symptoms
A review of 11 patients on using CBD for refractory status epilepticus (seizures of long duration or that occur very close to each other & are not well managed by drugs) shows how powerful it can be compared current options Cannabidiol in refractory status epilepticus: A review of clinical experiences https://pubmed.ncbi.nlm.nih.gov/36399869 “Patients were trialed on an average of 9 anti-epileptic drugs prior to CBD administration, after which 9 of the 11 patients experienced a reduction of seizure activity. Dosing of CBD ranged between 5-25 mg/kg/day and was titrated based on patient response to therapy. Adverse effects were relatively benign and were generally limited to gastrointestinal discomfort, reported after seizure cessation.”
In Sturge-Weber syndrome (a rare genetic disorder of the blood vasculature system), CBD helped with seizure control, anxiety, emotional regulation & quality of life Cannabidiol Treatment for Neurological, Cognitive, and Psychiatric Symptoms in Sturge-Weber Syndrome https://pubmed.ncbi.nlm.nih.gov/36508880
A comprehensive review of using CBD for neurodegenerative disorders Cannabidiol for neurodegenerative disorders: A comprehensive review https://pubmed.ncbi.nlm.nih.gov/36386183 And a literature review of using cannabis & CBD for neurodegenerative disorders Cannabis sativa and Cannabidiol: A Therapeutic Strategy for the Treatment of Neurodegenerative Diseases? https://pubmed.ncbi.nlm.nih.gov/36467781
In a safety study of children with autism, treatment with a 20:1 CBD:THC solution caused no significant differences in the safety biomarkers measured Medical cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder: An interim analysis of biochemical safety https://pubmed.ncbi.nlm.nih.gov/36249785
A review of autism & why using cannabinoids seems to help with a number of the behavioral, cognitive, social interaction, hyperactivity, anxiety & sleep symptoms Implications of the endocannabinoid system and the therapeutic action of cannabinoids in autism spectrum disorder: A literature review https://pubmed.ncbi.nlm.nih.gov/36379443
In white blood cells battling HIV, CBD changes the expression of several genes related to the immune system & inflammation while a long-term CBD treatment reduced the spread of the virus Cannabidiol modulates expression of type I IFN response genes and HIV infection in macrophages https://pubmed.ncbi.nlm.nih.gov/36248834
In healthy humans, the safety, effects & flow through the body of Spectrum Yellow Oil (20 mg CBD + ~0.5 mg THC per mL)
Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Yellow Oil in Healthy Participants
A safety review of 24 studies on nabiximols (ie: Sativex – a 1:1 THC:CBD spray) Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports https://pubmed.ncbi.nlm.nih.gov/33749480
A review of animal studies on using CBD for chronic pain finds it causes “analgesic [painkilling] effects, decreasing hyperalgesia [extreme sensitivity to pain] & mechanical/thermal allodynia [pain from a a stimulus that does not normally provoke pain]” Chronic Pain and Cannabidiol in Animal Models: Behavioral Pharmacology and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/36355044
In pig eyes, CBD increased the flow of the aqueous humor (the fluid that contributes to the intraocular pressure important in eye diseases like glaucoma) via collagen contraction, the inhibition of myosin light chain (MLC) & myosin phosphatase targeting subunit 1 (MYPT1) & reduced activation of RhoA The Effects of Cannabidiol on Aqueous Humor Outflow and Trabecular Meshwork Cell Signaling https://pubmed.ncbi.nlm.nih.gov/36230968